Personalis, Inc. · NASDAQ:PSNL

Personalis — Merger or Acquisition (November 2026)

30 slides from Personalis's merger presentation, Nov 12, 2026

  1. Slide 1: Personalis acquisition by Tempus

    Investor Presentation Personalis acquisition by Tempus November 2026 © 2026 Personalis, Inc. All rights reserved. All trademarks are the property of Personalis, Inc. or their respective owners. All products described here are for Research Use Only and not for use in diagnostic procedures (except as

  2. Slide 2: $1.9bn Sale of Personalis to Tempus Maximizes Value to Shareholders

    $1.9bn Sale of Personalis to Tempus Maximizes Value to Shareholders Deal Terms Protect Shareholders While Providing Significant Upside Transaction was highly negotiated over the course of months amidst a competitive process and represents best terms reasonably available: Board negotiated downside pr

  3. Slide 3: Transaction Follows a Thorough, Fair Process

    Transaction Follows a Thorough, Fair Process Transaction Offers Compelling and Certain Value Stock Consideration Allows Participation in Potential Upside from Combination; Transaction Mitigates Significant Standalone Execution Risk Moderna / Merck News was Already Priced into Management Forecast and

  4. Slide 4: A Majority-Independent, Highly Qualified Board Led the Process

    A Majority-Independent, Highly Qualified Board Led the Process Karin Eastham Independent Chair of the Board • Director since 2019; Chair since 2022 • Chair of the Nominating & Governance Committee • Has served on the Veracyteboard of directors since 2012 • Former EVP and COO of the Burnham Institute

  5. Slide 5: The Board Ran a Robust Process

    The Board Ran a Robust Process Strategic relationship with Tempus began in 2023; extensive discussions, which began at much lower price points, culminated in today’s sale transaction Key Process Milestones November 2023 Signed NeXT Personal Dx collaboration with Tempus Personalis issued Tempus9.2M w

  6. Slide 6: Focused Negotiations Drove Tempus to Maximum Offer

    Focused Negotiations Drove Tempus to Maximum Offer Tempus increased value indicationfour times over course of negotiations, including an incremental bump beyond the stated highest achievable value of $15 / share +81% Increase vs. Tempus’ 28% Initial Indication(1) Premium to 30-Day VWAP(2) 3 Suitors

  7. Slide 7: Tempus Transaction Represents the Most Compelling Path Forward

    Tempus Transaction Represents the Most Compelling Path Forward The board carefully evaluated all potential alternatives Standalone Party A Tempus Headline Value Per Share n/a $17.00 Verbal final offer (7/16/26), down from $18.00–$20.75 range (Subject to additional diligence) $16.25 Final indication

  8. Slide 8: Key Terms and Final Deal Terms

    ($M, Except per Share Data) Key Terms Final Deal Terms Unaffected (7/16/26) 50% Cash All Stock Price Per Share $14.68 $16.25 $16.25 Cash Consideration Per Share 8.13 – Stock Consideration Per Share 8.13 16.25 Exchange Ratio at Signing (Tempus $52.47) – 0.1549x 0.3097x Fully Diluted Shares (M) 117.15

  9. Slide 9: Agenda

    Agenda Transaction Follows a Thorough, Fair Process Transaction Offers Compelling and Certain Value Stock Consideration Allows Participation in Potential Upside from Combination; Transaction Mitigates Significant Standalone Execution Risk Moderna / Merck News was Already Priced into Management Forec

  10. Slide 10: Personalis Stock Has Been Subject to Significant Volatility

    15% 34% 24% 14% 11% 0% 2% 1% 7% 35% 28% 29% $0 - $3 $3 - $6 $6 - $9 $9 - $12 $12 - $16.25 $16.25 - $18 $18 - $21 $21 - $24 Share Price Performance YTD Since 1/26 (2) 1-Yr 3-Yr 5-Yr Personalis +93% +49% +138% +603% (28%) Peers (1) +26% +17% +63% +45% (55%) $0 $5 $10 $15 $20 $25 $30Jul-21 Oct-21 Jan-2

  11. Slide 11: Price per Share Compared to Analyst Price Targets

    Price per Share Compared to Analyst Price Targets Source: Wall Street Research and FactSet. Ä Since Annc. Suspended Coverage Withdrew $17.00 PT – – – Increased PT from $11.00 to $16.25 Increased PT from $10.00 to $16.25 $18.00 Buy $17.00 Buy $13.00 Buy $13.00 Hold $11.00 Buy $11.00 Buy $10.00 Buy Br

  12. Slide 12: Transaction Compares Favorably to Precedent Deal Metrics

    Transaction Compares Favorably to Precedent Deal Metrics Personalis stockholders are receiving a valuation well above precedent benchmarks, at 15.2x EV / NTM revenue Represents ~2.4x the precedent median of 6.3x identified by both Centerview and TD Cowen Largest disclosed MRD-focused acquisition to

  13. Slide 13: Implied Multiple Higher Than Publicly Traded Companies

    Implied Multiple Higher Than Publicly Traded Companies at the Time of the Transaction 18.9x 18.3x 16.0x 14.6x 14.6x 13.9x 8.8x 7.8x 4.6x 4.5x 4.0x Source: Public filings and FactSet as of 10/28/2026. (1) Reflects multiple based on management revenue forecast. EV / 2026E Revenue Median: 11.3x Transac

  14. Slide 14: Agenda

    Agenda Transaction Follows a Thorough, Fair Process Transaction Offers Compelling and Certain Value Stock Consideration Allows Participation in Potential Upside from Combination; Transaction Mitigates Significant Standalone Execution Risk Moderna / Merck News was Already Priced into Management Forec

  15. Slide 15: Merger Is the Best Path for Personalis Stockholders

    Merger Is the Best Path for Personalis Stockholders, and Tempus Is the Best Partner Remaining independent carries significant operational execution risk Personalis must compete against substantially larger MRD incumbents in a highly competitive space Current unit economics for Personalisare unfavora

  16. Slide 16: Scale is Increasingly Important in Competitive Dx Landscape

    Scale is Increasingly Important in Competitive Dx Landscape 2026E Revenue ($bn) Source: Public filings and FactSet. (1) Reflects 2026E revenue numbers from Exact Sciences DEFM14A. (2) Guardant has indicated it is developing a personalized MRD offering. (3) Reflects implied offer value. MRD Offering?

  17. Slide 17: Standalone Plan Requires ~$525M of Dilutive New Equity

    $8.7B $13.6B $13.6B $1.0B $1.5B $0.8B $1.5B $1.1B 036912 15 $18 0 10 20 30 40 50 60 2019 2020 2021 2022 2023 2024 2025 2026 YTD # IPOs # FOs # RDs Total ($B) Standalone Plan Requires ~$525M of Dilutive New Equity Projections Under Management Plan ($M)(2) Source(s): Personalis Schedule 13E-3/A (filed

  18. Slide 18: A Superior Alternative to Tempus is Highly Unlikely

    Source(s): PersonalisDEFM14A (filed 10/21/26), Personalis Schedule 13E-3/A (filed 10/20/26), Tempus Form S-4/A (filed 10/20/26), Personalis Form 10-K for FY2025 and Form 8-K (filed 10/6/26), Tempus Form S-4 (filed 8/31/26), and Schedule 13E-3 (filed 8/31/26), Natera, Roche and CareDx press releases.

  19. Slide 19: Agenda

    Agenda Transaction Follows a Thorough, Fair Process Transaction Offers Compelling and Certain Value Stock Consideration Allows Participation in Potential Upside from Combination; Transaction Mitigates Significant Standalone Execution Risk Moderna / Merck News was Already Priced into Management Forec

  20. Slide 20: Personalis' NeXT Platform Supports Moderna / Merck Cancer Vaccine Program

    Since program inception: Personalis’ ImmunoID NeXT platform has supported tumor profiling for Moderna / Merck’s personalized cancer vaccine program, intismeran autogene(V940 / mRNA-4157), since clinical development began December 13, 2022: Moderna / Merck announce positive Phase 2b KEYNOTE-942 resul

  21. Slide 21: Framing the Market Opportunity for Intismeran Autogene

    Framing the Market Opportunity: Majority of Intismeran Autogene Total Opportunity for Moderna Remains High Risk Source: Wall Street research and public filings. (1) Sponsor estimate for the primary endpoint; interim analyses can read out earlier (INTerpath-001 read out at a pre-specified interim in

  22. Slide 22: Moderna PCV Revenue Included in Forecast at 100% Probability

    Revenue from Moderna’s PCV Was Included in the Personalis Forecast at 100% Probability Prior to Release of INT Data Management Forecast Per 6/5/26 Board Discussion 22 Personal Cancer Vaccine segment provides estimate of Moderna collaboration impact to Personalis Management base case forecast contemp

  23. Slide 23: Forecast Implied Multi-Blockbuster Revenue for Moderna's PCV

    Personalis’ Forecast Implied Multi-Blockbuster Revenue for Moderna’s PCV – Well in Excess of Street Expectations Mgmt. Implied 2034 Intismeran Autogene Revenue to Moderna Current Intismeran Autogene Sentiment Among Wall Street Brokers Personalis management forecast implies Moderna’s intismeran autog

  24. Slide 24: Moderna Performance Is Not A Clear Comparator for Personalis

    Moderna Performance Is Not A Clear Comparator for Personalis Personalis management assumes commercial success of intismeran autogene in a broad patient population At ~$1,000 / test of revenue considered for Personalis, economics are vastly different than those to Moderna Moderna (in addition to Merc

  25. Slide 25: Appendix

    25 Appendix

  26. Slide 26: Personalis, Inc. company overview

    An ultrasensitive, tumor-informed MRD platform with established Medicare coverage and leading partners Personalis, Inc. (Nasdaq: PSNL) Fremont, CA-based cancer genomics company focused on ultrasensitive, tumor-informed MRD testing 2011 Launched&IPO in 2019 ~260 Employees ~571K Human Samples Sequence

  27. Slide 27: Tempus Overview

    Business Overview Tempus Overview Source: Company filings. Fast-growing healthcare technology company providing diagnostics solutions, leveraging AI to connect laboratory results to a patient’s own clinical data, providing personalized results Genomics, which leverages laboratories to provide NGS di

  28. Slide 28: Forward-Looking Statements

    Forward-Looking Statements This communication relates to a proposed business combination transaction between Tempus AI, Inc. (“Tempus”) and Personalis, Inc. (“Personalis”). This communication includes forward-looking statements within the meaning of federal securities laws. Forward-looking statement

  29. Slide 29: Additional Information and Where to Find It

    Additional Information and Where to Find It In connection with the proposed merger, Tempus filed with the SEC a registration statement on Form S-4 which includes a document that serves as a prospectus of Tempus and a proxy statement of the Company (the “proxy statement/prospectus”). Tempus, the Comp

  30. Slide 30: No Offer or Solicitation

    No Offer or Solicitation This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer,

Personalis — Merger or Acquisition (November 2026) on 6ix